Furthermore, they showed that HDACi such as LBH589 may be useful for the treatment of IPF, interfering with fibroblast to myofibroblasts differentiation, and more importantly leading to the downregulation of ACTA2 and ECM genes such as COL1A1, COL3A1, and FN in primary IPF fibroblasts. Here, ACTA2 is linked to idiopathic pulmonary fibrosis.